A Phase 2, Single-Arm, Multicenter Trial of Zanzalintinib in Combination With Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer

Summary

The primary purpose of the study is to evaluate the effectiveness of zanzalintinib in combination with pembrolizumab as first-line maintenance therapy in participants with metastatic squamous NSCLC.

Eligibility

Age range

18+ years

Sex

All

Healthy volunteers

No

Interventions

• Drug
  Carboplatin

  Administered as part of SOC therapy as specified in the treatment arm.

• Drug
  Paclitaxel

  Administered as part of SOC therapy as specified in the treatment arm.

• Drug
  Nab-paclitaxel

  Administered as part of SOC therapy as specified in the treatment arm.

• Drug
  Pembrolizumab

  Administered as specified in the treatment arm.

• Drug
  Zanzalintinib

  Administered as specified in the treatment arm.

Location